Daiichi Sankyo Sponsored Research

Guidelines for Application

Application is on email basis. Please send us one page summary of the proposal at the program office (External_Innovation@dsi.com).

Eligibility: Researchers affiliated with universities and research institutions, who have ideas which may lead to drug discovery. The program is not open to undergraduate or graduate students.

Research Budget: up to $230,000 for one year including overhead/indirect costs

Term: 1-3 years. Successful program(s) will be considered for staging into collaborative research.

Selection Criteria:

- Matching needs (Research interests)
- Originality and uniqueness of research
- Drug discovery potential
- Feasibility of research plan
- Non-redundancy with Daiichi Sankyo's internal research projects and current collaboration

Deadline: Rolling application (until March 2024)

Research Interests

Oncology

I. Novel targeted protein degradation technologies such as tumor/tissue selective E3 ligands and degradation mechanism other than ubiquitin proteasome system
II. Novel, biologically-tractable, tumor-associated antigens and their binders such as monoclonal antibody/antibody mimetics/Fab/scFv/sdAb
III. Novel IO targets for which mechanisms are confirmed in human-derived samples
IV. Adoptive cell-therapy technologies that can successfully treat solid tumors
V. Pancreatic cancer in vivo model that reflects human pancreatic ductal adenocarcinoma
VI. In vitro assay system that reflects in vivo epigenetic status and mechanism analysis of epigenetics targeting small molecule compounds

Non-Oncology

I. Novel disease relevant target identification research by using patient tissue samples or genetical analysis for the following target diseases (* both are neuroinflammation perspective)
   a) Immune diseases: refractory immune diseases and lung fibrosis
   b) Neurodegenerative diseases*: Alzheimer’s disease, Perkinson’s disease and ALS
   c) Psychiatric diseases*: Schizophrenia, Autism spectrum disorder, addiction & anxiety, major depression disorders
d) Rare diseases: CNS, liver (mono or double genetic)
e) Heart failure & Liver disease: (HFrEF & HFrEF) & NASH (not TG reducer)
f) Ophthalmological disorders (AMD, RP and PDR)
II. Novel in vitro (iPSC derived) and in vivo models that recapture human pathological mechanisms/conditions of immune and CNS disorders described above
III. Biomarker research for patient stratification in neuroinflammation derived disease described above
IV. Drug delivery technologies for siRNAs to brain, heart, lung & kidney
V. Novel RNA targeting small molecules & editing technologies (not RNase2, Ago2 & ADAR) with CNS diseases and rare diseases target
VI. AAV platform: new capsid library (CNS target)

Further information is available on our website below.
https://www.daiichisankyo.com/rd/strategy_operations/open_innovation/our_interests/

Parallel Application to Other non-Daiichi Sankyo Grants

Public Grant
DS may accept an application for a research topic by an individual that has already applied for a public grant for such research topic so long as the applicable intellectual property is controlled by either the PI and/or university.

Pharma-Sponsored Grant
DS may accept an application for a research topic by an individual that has already applied for a private grant for such research topic, but DS reserves the right to decline such application for any reason, including if such individual accepts a private grant.

Please feel free to contact us for any inquiries (External_Innovation@dsi.com).